Decision Analysis Dr M G Dawes Centre for Evidence Based Medicine.

Slides:



Advertisements
Similar presentations
Comparing different treatments How can we decide?.
Advertisements

Health Economics for Prescribers
Definitions Patient Experience Patient experience at NUH results from a range of activities that all impact upon patient care, access, safety and outcomes.
Relieving distress, transforming lives Data Collection in IAPT The Importance of collecting data in IAPT-compliant services (References: The IAPT Data.
LSU-HSC School of Public Health Biostatistics 1 Statistical Core Didactic Introduction to Biostatistics Donald E. Mercante, PhD.
Scaling Session Measurement implies “assigning numbers to objects or events…” Distinguish two levels: we can assign numbers to the response levels for.
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
Making Decisions in Health Care: Cost-effectiveness and the Value of Evidence Karl Claxton Centre for Health Economics, Department of Economics and Related.
Decision Tree Analysis. Decision Analysis Managers often must make decisions in environments that are fraught with uncertainty. Some Examples –A manufacturer.
Shared decision making and Australian general practitioner training Dr Ronald McCoy, Education Strategy Senior Advisor, Royal Australian College of General.
99.98% of the time patients are on their own “The diabetes self-management regimen is one of the most challenging of any for chronic illness.” 0.02% of.
Decision Analysis Prof. Carl Thompson
Optimal Drug Development Programs and Efficient Licensing and Reimbursement Regimens Neil Hawkins Karl Claxton CENTRE FOR HEALTH ECONOMICS.
Decision Analysis. What is decision analysis? Based on expected utility theory Based on expected utility theory Used in conditions of uncertainty Used.
The sources and quality of information for patients Andrew Herxheimer International Society of Drug Bulletins (ISDB) & Database of Individual Patients’
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Introduction to decision modelling Andrew Sutton.
The Cost-Effectiveness and Value of Information Associated with Biologic Drugs for the Treatment of Psoriatic Arthritis Y Bravo Vergel, N Hawkins, C Asseburg,
Journal Club Alcohol and Health: Current Evidence March-April 2006.
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
Vanderbilt Sports Medicine Chapter 4: Prognosis Presented by: Laurie Huston and Kurt Spindler Evidence-Based Medicine How to Practice and Teach EBM.
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
DISCUSSION Alex Sutton Centre for Biostatistics & Genetic Epidemiology, University of Leicester.
Are the results valid? Was the validity of the included studies appraised?
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Performance Measurement and Analysis for Health Organizations
Smart use of antibiotics: building confidence in new approaches Dr. Hayley Wickens.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
National Obesity Observatory The Standard Evaluation Framework National Obesity Observatory The Standard Evaluation Framework Kath Roberts
Measuring Health Outcomes
HTA – Cost Containment or Quality Instrument? Bengt Jönsson Stockholm School of Economic.
Economic evaluation of drugs for rare diseases CENTRE FOR HEALTH ECONOMICS K Claxton, C McCabe, A Tsuchiya Centre for Health Economics and Department of.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Vanderbilt Sports Medicine Chapter 5: Therapy, Part 2 Thomas F. Byars Evidence-Based Medicine How to Practice and Teach EBM.
Step Four Choosing Therapy Component 2/Unit 4a4 Health IT Workforce Curriculum Version 1.0/Fall
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
Centre for Evidence-Based Medicine EBM and E-B Guidelines l EBM integrates evidence, expertise, and the unique biology and values of individual patients.
Critical Appraisal (CA) I Prepared by Dr. Hoda Abd El Azim.
PTP 661 EVIDENCE ABOUT INTERVENTIONS CRITICALLY APPRAISE THE QUALITY AND APPLICABILITY OF AN INTERVENTION RESEARCH STUDY Min Huang, PT, PhD, NCS.
Decision Analytic Approaches for Evidence-Based Practice M8120 Fall 2001 Suzanne Bakken, RN, DNSc, FAAN School of Nursing & Department of Medical Informatics.
EBM --- Journal Reading Presenter :呂宥達 Date : 2005/10/27.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
EBM --- Journal Reading Presenter :葉麗雯 Date : 2005/10/27.
Research Design Evidence Based Medicine Concepts and Glossary.
Validity and utility of theoretical tools - does the systematic review process from clinical medicine have a use in conservation? Ioan Fazey & David Lindenmayer.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
Promoting Patient Involvement in Medication Decisions David H. Hickam, MD, MPH Professor, Dept. of Medicine Oregon Health & Science University Portland,
Why does SMC say NO We all want the most effective medicines All medicines cost money Health budgets are limited How do we choose?
Health and Wellbeing Impacts of Green and Blue Infrastructure: Critical Issues for Application of Cost Benefit Analysis for Policy Appraisal Dr Tim Taylor.
Managing Osteoarthritis of the Knee
IE 485 «Decision Making in Health Care»
Benjamin Kearns, The University of Sheffield
Cost effectiveness Analysis: Valuing Health; Valuing Research!
USING NATIONAL GUIDELINES FOR SCREENING, TREATMENT, AND FOLLOW-UP
Statistical Core Didactic
Research and Evidence Based Medicine
Making Decisions With Your Osteoarthritis Patients
The valuation of disease-specific questionnaires for QALY analysis
Health care decision making
Dissemination of CPRs: focus on Clinical Decision Support Systems (CDSS) Dr Emma Wallace.
Evidence-based Medicine Curriculum
Analysing RWE for HTA: Challenges, methods and critique
Evidence Based Practice
Measuring outcomes Emma Frew October 2012.
Introduction to Evidence Based Medicine
Presentation transcript:

Decision Analysis Dr M G Dawes Centre for Evidence Based Medicine

Contents What is Decision Analysis? Decision Trees How they work Critical Appraisal of Decision Analysis A bit on economics An example of some software

What is Decision Analysis? Urinary Tract Infection Patient presents with symptoms What would happen if you opted for one path in preference to another On what basis would you assess outcome

How does one start? List all the options and display: Commonly accepted format is a tree diagram. UTI Decision Node Treat Don’t Treat

Decision data UTI Chance Node Treat Don’t Treat better Not better better Not better

Result 0.9 is better than 0.2 UTI Chance Node Treat Don’t Treat better Not better better Not better

Add reality to probability scores Cost of tests Cost of treatment Days lost from work Cost of re attending clinician Multiply the probabilities by the costs

Cost Data UTI Treat Don’t Treat better Not better better Not better Costs

Rollback Costs UTI Treat Don’t Treat better Not better better Not better (2*0.9) + (9*0.1)=2.7 (0.2*2)+(0.8*9)=7.6

Results More people get better (90 % vs 20%) It is cheaper (2.70 vs 7.60)

What does the patient think? Utilities How would you feel? QALYs Quality adjusted life year

QALY’s From Alastair Gray

Time Trade Off Method (to assess utility of a health state) You have arthritis (severe - unable to walk to shops – need a buggy – in pain most of the time) and are aged 48 Choose between living with arthritis until 80 or living in perfect health for a shorter length of time eg If 70 – Etc until chosen a year

Time Trade Off Utility is 1- (number of years willing to give up/(80-current age) If age selected was 75 Utility = 1-(80-75)/(80-48) = 0.84 The better your health the less the years you give up

Trade Off vs Age

Utilities UTI Treat Don’t Treat better Not better better Not better Utilities

Rollback UTI Treat Don’t Treat better Not better better Not better (9*0.9) + (2*0.1)=8.3 (0.2*9)+(0.8*2)=3.4

Results More people get better (90 % vs 20%) It is cheaper (2.70 vs 7.60) The utilities are better (8.3 vs 3.4) Probably should treat?? Sensitivity analysis

UTI: What are the options? Treat on symptoms alone Treat after doing a test Exercise : what are the options Diagnosis Therapy Outcome

How does one develop this? Need to know all the baseline data. For UTI What proportion of patients with typical symptoms have UTI What is the sensitivity and specificity of a dipstix. What is the success rate of antibiotic treatment?

On what basis would you assess outcome? Bacterial eradication Symptoms Diary Questionnaire Interview Time off work What do patients think?

How are these studies appraised Are the results valid What are the results Can these be applied to my patients

Are the results valid? Were all important strategies and outcomes included? Were all of the realistic clinical strategies compared? Were all clinically relevant outcomes considered? Was an explicit and sensible process used to identify, select and combine the evidence into probabilities?

Validity Check (2) Were the utilities obtained in an explicit and sensible way from credible sources? Was the potential impact of any uncertainty in the evidence determined?

What are the Results? In the baseline analysis, does one strategy result in a clinically important gain for patients? If not, is the result a toss-up? How strong is the evidence used in the analysis? Could the uncertainty in the evidence change the result?

Can I apply the results to my patient? Do the probability estimates fit my patients' clinical features? Do the utilities reflect how my patients would value the outcomes of the decision?

Bottom Line The power of decision analysis is not in the numbers at the decision node It is the ability to change the utilities and probabilities Watching how this affects the decision node Thus it should be seen as a dynamic tool Software for this is available

EXCEL or ‘Nice’ system ‘Quite’ friendly Free download to try US$ 295 academic price